Houston, May 3, 2023 – NuProbe, a genomics company developing ultrasensitive research assays for detecting and monitoring low-frequency mutations, gene…
Read More
HERCULES, Calif. and Houston, Texas— November 4, 2022 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in…
Houston, TX, Jun 02, 2022 — NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M…
SADDLE approach uses computational primer design to minimize primer-dimer formation, and thus does not require enzymatic primers and primer-dimer removal.
The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embedded (FFPE) tissue samples and from cell-free DNA (cfDNA) samples1.
NuProbe published research demonstrating new technology to qualitatively and quantitively detect multiple low-frequency variants in one quantitative PCR (qPCR) reaction.
By integrating molecular barcoding technology with the Blocker Displacement Amplification (BDA) allele enrichment, the team invented the new quantitative BDA (QBDA) method that overcomes potential biases in BDA to enable accurate VAF quantitation.
The deal will combine C2i’s AI-driven cancer intelligence platform with NuProbe’s advanced sequencing technology to power pharma and diagnostic services.
OCEANS enables rapid, accurate, and affordable detection of somatic mutations as low as 0.05% VAF. This novel research will facilitate the development of same-day, low-cost oncology panels for time-sensitive therapy selection and recurrence monitoring.
NuProbe will integrate QASeq and BDA technologies with Bionano’s Saphyr system for research and product development in the fields of reproductive health and oncology liquid biopsies.
